R&D Center for Photodynamic Therapy Drug, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., No. 308, Cailun Rd., Shanghai 201210, PR China.
Photodiagnosis Photodyn Ther. 2012 Jun;9(2):180-5. doi: 10.1016/j.pdpdt.2011.09.004. Epub 2011 Oct 28.
The second generation photosensitizer Hemoporfin (7(12)-(1-methoxyethyl) -12(7)-(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H,23H-porphin-2,18-dipropionic acid) is a porphyrin derivative which processes a stable structure, high singlet oxygen yield, high photoactivity, low dark toxicity and fast clearance rate. Hemoporfin, also known as hematoporphyrin monomethyl ether (HMME) has been studied and used in photodynamic therapy (PDT) in China since 1989. This series of reports will provide an overview on the preclinical and clinical studies of this PDT photosensitizer. The first part of this series will highlight the results of preclinical studies that focused on the compound's optical characteristics, mechanism of the activities, pharmacological and toxicological properties.
第二代光敏剂血卟啉（7(12)-(1-甲氧基乙基）-12(7)-(1-羟乙基）-3,8,13,17-四甲基-21H,23H-卟啉-2,18-二丙酸）是一种卟啉衍生物，具有稳定的结构、高单线态氧产率、高光活性、低暗毒性和快速清除率。血卟啉，又称血卟啉单甲醚（HMME），自 1989 年以来，在中国已被用于光动力疗法（PDT）的研究和应用。本系列报告将概述该 PDT 光敏剂的临床前和临床研究。本系列的第一部分将重点介绍侧重于该化合物光学特性、作用机制、药代动力学和毒理学特性的临床前研究结果。
